Disclosures for "A Phase 2, Randomized, Placebo-Controlled Trial to Evaluate the Effects of SAGE-718 in Patients with Alzheimer's Disease: Study Design")
-
Dr. Lago has received personal compensation for serving as an employee of Sage Therapeutics. Dr. Lago has stock in Sage Therapeutics.
-
Aaron Koenig has received personal compensation for serving as an employee of Sage Therapeutics.
-
Dr. Johannesen has received personal compensation for serving as an employee of Sage Therapeutics. Dr. Johannesen has stock in Sage Therapeutics . Dr. Johannesen has received research support from National Institute of Health. Dr. Johannesen has received research support from Brain & Behavior Research Foundation . Dr. Johannesen has received research support from VA office of Rehabilitation Research & Development.
-
Dr. Park has nothing to disclose.
-
Sigui Li has received personal compensation for serving as an employee of SAGE Therapeutics.
-
Ms. Freitag has nothing to disclose.
-
Jeffrey Wald has received personal compensation for serving as an employee of Sage Therapeutics. Jeffrey Wald has received stock or an ownership interest from Sage Thereapeutics.
-
Dr. Paumier has nothing to disclose.
-
Michael Quirk has received personal compensation for serving as an employee of Sage Therapeutics. Michael Quirk has received stock or an ownership interest from Sage Therapeutics.
-
Dr. Doherty has received personal compensation for serving as an employee of Sage Therapeutics. Dr. Doherty has received stock or an ownership interest from Sage Therapeutics.